Placebo-controlled trial double-blind clinical trial to evaluate the efficacy of the RUTI® against SARS-CoV-2 infection

Type of project

Clinical trial to evaluate the protection of the RUTI® vaccine in health professionals at risk of infection with 200 receiving the vaccine and 100 receiving a placebo.

Brief description and objectives

In the absence of a definitive vaccine and in order to accelerate the availability of drugs to combat the SARS-CoV-2 virus the Catalan public health system has fast-tracked studies to re-purpose known and tested therapies and test their efficacy against the virus. This study uses a vaccine made from fragments of bacteria that is in the final stages of clinical testing as a treatment for tuberculosis infections. The vaccine strengthens the innate immune system of subjects and the objective is to verify if this provides more resistance to the new virus for health workers. The RUTI® vaccine has been developed by the company Archivel Farma from an original discovery made by Dr Cardona.

Project leader

Pere-Joan Cardona, IGTP

Project members

With the collaboration of the IDIAP-Jordi Gol Foundation
Archivel Farma

Projected timing

6 months

Funding bodies

The Ministry of Health and the Department of Research and Innovation of the Department of Health (DGRIS) of the Government of Catalonia with the collaboration of AQuAS and Biocat

Associated News

Two projects at the IGTP and IDIAP Jordi Gol research centres focus on the immune response of health professionals to infection with SARS-CoV-2